PA
ADAP

Procyon Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

Procyon Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13,000
Closed -$20.5K – 519
2024
Q1 		$20.5K Buy
+13,000
New +$15.7K ﹤0.01% 508

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Procyon Advisors's ADAP Position: Q2 2024 in Review

Procyon Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q2 2024, closing a stake of 13,000 shares — an estimated $20.5K sold.

Procyon Advisors first reported a position in ADAP in Q1 2024 and held it in 1 quarter. The position peaked at $20.5K in Q1 2024. 76 funds tracked by Wall St. Rank hold ADAP as of Q2 2024.

  • Procyon Advisors reported no remaining Adaptimmune Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Procyon Advisors sold 13,000 Adaptimmune Therapeutics shares in Q2 2024, an estimated $20.5K.
  • Procyon Advisors first reported a position in Adaptimmune Therapeutics in Q1 2024 and held it in 1 quarter.
  • Procyon Advisors's Adaptimmune Therapeutics position peaked at $20.5K in Q1 2024.
  • 76 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2024.

Based on Procyon Advisors's 13F filing for Q2 2024, filed 2 Aug 2024.